My Account Log in

1 option

Future research needs on procalcitonin-guided antibiotic therapy : identification of future research needs from Comparative effectiveness review no. 78 / investigators, Hussein Z Noorani, Elizabeth Adams, David Pitrak, Suzanne Belinson, Naomi Aronson.

NCBI Bookshelf Available online

View online
Format:
Book
Government document
Author/Creator:
Noorani, Hussein Z., author.
Adams, Elizabeth, author.
Pitrak, David, author.
Belinson, Suzanne, author.
Aronson, Naomi, author.
Blue Cross and Blue Shield Association. Technology Evaluation Center, author.
Contributor:
United States. Agency for Health Care Policy and Research, issuing body.
Blue Cross and Blue Shield Association. Technology Evaluation Center, author.
Series:
Future research needs paper ; no. 29.
AHRQ publication ; no. 13-EHC034-EF.
NCBI Bookshelf.
Future research needs papers ; number 29
AHRQ publication ; no. 13-EHC034-EF
NCBI Bookshelf
Language:
English
Subjects (All):
Calcitonin--therapeutic use.
Sepsis--drug therapy.
Anti-Bacterial Agents--therapeutic use.
Biomarkers.
Comparative Effectiveness Research.
Treatment Outcome.
Medical Subjects:
Calcitonin--therapeutic use.
Sepsis--drug therapy.
Anti-Bacterial Agents--therapeutic use.
Biomarkers.
Comparative Effectiveness Research.
Treatment Outcome.
Physical Description:
1 online resource (1 PDF file (various pagings)) : illustrations.
Place of Publication:
Rockville (MD) : Agency for Healthcare Research and Quality (US), January 2013.
Summary:
Sepsis is a serious condition with high morbidity and mortality for which clinical diagnostic criteria lack sensitivity and specificity. Early initiation of appropriate antibiotics and goal-directed therapies reduce mortality. Conversely, overuse and misuse of antibiotics, including continuing antibiotics longer than necessary for cure can result in adverse events and add to the increasing problem of antibiotic resistance. Several serum biomarkers have been identified in recent years that have the potential to help diagnose local and systemic infections, differentiate bacterial and fungal infections from viral syndromes or noninfectious conditions, prognosticate, and ultimately guide management, particularly antibiotic therapy. Among these, procalcitonin is the most extensively studied biomarker. Numerous studies have investigated the potential roles of procalcitonin in diagnosing and managing local and systemic infections. However, its clinical utility in the diagnosis and management of patients with suspected infections remains unclear.
Notes:
Augmentation of Procalcitonin-guided antibiotic therapy / investigators, Nilam J. Soni ... [et al.]. [2012].
Includes bibliographical references.

The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.

Find

Home Release notes

My Account

Shelf Request an item Bookmarks Fines and fees Settings

Guides

Using the Find catalog Using Articles+ Using your account